A seventh Victorian patient has been hospitalised with acute liver toxicity after using counterfeit retatrutide, with severe injury occurring after a second dose of the unapproved peptide. The cluster, which has emerged within weeks of use and caused jaundice, has prompted testing of the products…
A seventh Victorian patient has been hospitalised with acute liver toxicity after using counterfeit retatrutide , and the liver specialist managing the cluster has ordered testing of the products on the hypothesis that a contaminated batch is circulating in the state. The latest patient developed severe liver injury after a second dose of an unregulated peptide labelled as retatrutide. The case was reported by Caitlyn Gribbin and Rachel Carbonell, national health equity reporters at the ABC, and published on Monday 24 August 2026 at 2:25 pm.
Dr Marie Sinclair, a liver transplant specialist who has treated liver failure patients in Victoria, said the newest case followed the pattern of the earlier ones. "We have seen a recent case again, fairly similar to previous cases, where after a second dose of unregulated retatrutide there was severe liver injury." She has commissioned testing of the counterfeit peptides used by the liver failure patients, but no results are available yet, and she emphasised that contamination is only a hypothesis. "It's uncertain as to why this has happened, but one possibility is that there could be a contaminated batch of counterfeit retatrutide that is in Victoria."
In the affected patients, liver injury appeared within a few weeks of taking black market retatrutide and could produce jaundice and severe illness. Acute liver injury of this sort means hepatocellular damage sufficient to raise transaminase levels and bilirubin, with jaundice as the visible marker; at the severe end of the spectrum it approaches acute liver failure, the condition a transplant specialist is called upon to manage. Seven hospitalised patients in one state is a substantial cluster for any drug-induced liver injury. The exact date of the latest hospitalisation was not stated in the report, and Victoria's health department, which had previously warned that products labelled retatrutide may contain contaminants with toxic effects, was approached for comment on the new case but did not respond.
The geographic concentration is the strongest clue available. Robyn Langham, chief medical advisor to the Therapeutic Goods Administration TGA , said the localised nature of the Victorian cluster suggested a batch problem rather than a pattern distributed across the country. "We are seeing reports of acute liver failure which might be related to some batch issues certainly from Victoria." The cluster, she said, did not appear to be happening elsewhere in Australia.
The logic is straightforward. A counterfeit product that is intrinsically hepatotoxic would be expected to injure users wherever it is sold, producing a dispersed pattern of cases across states. Injuries concentrated in one state point to something more specific, such as a single contaminated batch that reached Victoria and not other markets.
The cluster must be read with caution. Victoria's health department had already warned about toxic contaminants in products labelled retatrutide, and Victorian liver units were alert to the problem, so clinicians there were more likely to test for and report these injuries. That awareness bias could make the cluster look more exclusive than it is. Langham has said hospital admissions are happening across the country because of unapproved peptide use, and the TGA is particularly concerned about adolescents and young children buying and injecting these products. The only cross-state data point available is Canberra: Canberra Health Services confirmed it had detected liver damage from products sold as retatrutide, but declined to say how many cases, citing low numbers. That confirmation shows the injury is not literally confined to Victoria; the withheld count leaves the national picture unknown.
Langham also drew a firm line between the black market material and the regulated investigational drug. "The retatrutide that's being sold is not the retatrutide that's currently in clinical trials." She said her comments were not the result of an investigation. The absence of a formal investigation matters for interpretation: the batch hypothesis is epidemiological inference, not a conclusion from a traced product or a matched sample, and no process has yet been announced that would confirm or exclude it.
Manny Simons, general manager of Lilly Australia, warned that any retatrutide available online is unapproved and unverified. Eli Lilly is the sole owner of the patent for retatrutide and is currently running clinical trials of the peptide.
The TGA has been running parallel enforcement operations against the unapproved peptide market. This year, in collaboration with the Australian Border Force, the agency has destroyed more than 94,500 unapproved peptide products. In April, authorities seized $2 million worth of steroids and peptides. In the week before 24 August, TGA investigators and New South Wales Police seized more than $120,000 of illicit peptide and anabolic steroid products from premises allegedly linked to social media influencers. The exact dates of the seizures were not given beyond that general timing.
Langham's position is categorical: there are no safe unapproved peptides. The TGA has issued the same warning publicly, stating that black market retatrutide is a counterfeit product and that no unapproved peptide is safe for human use. The reason is structural rather than specific to retatrutide. An unapproved peptide carries no verified identity, no measured dose, no controlled impurity profile, and no assurance of sterile manufacture. A buyer cannot know that the vial contains the stated peptide at the stated concentration, or that it contains only that peptide.
The enforcement numbers describe a market large enough to absorb repeated losses. More than 94,500 destroyed products, a $2 million seizure in April, and a further $120,000 seizure in a single week presume an inventory that keeps regenerating. The alleged link to social media influencers is consistent with how these products reach buyers: this year has seen a boom in social media promotion of counterfeit, unapproved peptides, and the seizure was made from premises allegedly linked to influencers rather than from conventional retail channels.
The specific legal provisions under which the seizures and destruction were carried out were not stated. The involvement of the Australian Border Force points to import controls, and the involvement of New South Wales Police points to criminal investigation of the supply network, but the precise statutory basis remains unspecified.
Two families of explanation exist for the Victorian injuries, and the observed timing fits both.
Drug-induced liver injury is usually divided into direct and idiosyncratic forms. Direct injury is caused by a substance that is inherently toxic to hepatocytes; the damage is dose-related and largely predictable. Idiosyncratic injury involves an immune or metabolic reaction in a susceptible person, is not dose-dependent in the same way, and often appears after a delay. The pattern reported in Victoria, severe injury after a second dose within a few weeks of first use, is consistent with either mechanism. A directly toxic contaminant could accumulate across doses until it crosses a threshold; an immune reaction could be primed by the first dose and amplified by the second, with the second exposure triggering clinically apparent injury.
The distinction is not academic. If a hepatotoxic contaminant is responsible, other users of the same batch remain at risk, and laboratory testing can identify the substance and allow tracing of the batch. If the injury is idiosyncratic, most users of the same product would escape injury, and batch testing might reveal nothing unusual. The two outcomes demand different responses, and identifying which applies is the central value of the testing Dr Sinclair has commissioned.
What could be in a counterfeit peptide that is not in regulated material? Peptide manufacture has known failure modes that unregulated production does not control: residual reagents from solid-phase synthesis, trace acids such as trifluoroacetic acid carried over from high-performance liquid chromatography purification, oxidation and deamidation products that form during storage, truncated sequences from incomplete synthesis, and microbial or endotoxin contamination from non-sterile handling. There is also the possibility of a more basic error: the vial could contain the wrong peptide, a different dose than labelled, or a mixture of several substances. None of these candidates is confirmed in this cluster, and Dr Sinclair has said there are no testing results yet; the contaminated-batch explanation remains a hypothesis.
If testing finds a defined hepatotoxic contaminant, the next step is batch tracing: matching patient-sourced vials against seized product and against a common production or distribution source. If testing finds nothing, the investigation shifts to the patients themselves, including host factors, interactions with other substances, or an immune response to the peptide or its impurities. The clinical trial record for genuine retatrutide cannot settle the question, because the counterfeit product is a different material.
Peptides are small chains of amino acids that act as signalling agents in the body, and many are now produced synthetically for medicine. Regulated peptide medications include insulin, a mainstay of diabetes treatment for a century, and GLP-1 medications such as Ozempic , which mimic the incretin hormone glucagon-like peptide-1 to regulate blood sugar and appetite.
Retatrutide belongs to a newer generation. It is a triple receptor agonist , activating the GIP, GLP-1, and glucagon receptors. GLP-1 receptor activation stimulates insulin secretion in a glucose-dependent manner, suppresses appetite, and slows gastric emptying. GIP, the other major incretin, also potentiates insulin secretion. Glucagon receptor activation increases energy expenditure and hepatic glucose output. The combination is being studied for weight loss and metabolic control, and the emerging phase 3 literature, including the TRANSCEND-T2D-1 trial published in The Lancet, supports the value of the approach.
The demand for retatrutide is precisely the problem. Because the drug has shown promise in clinical trials, public demand exists now, while the regulated supply does not. Prescription GLP-1 medicines are available through approved channels, but a triple agonist still in development is not, and the gap between demand and supply is what the counterfeit market fills.
Against the counterfeit market stands a large, controlled clinical development program. Peptide Atlas registry records on file list 33 registered clinical trials for retatrutide. The phase breakdown is: Phase 3: 6 trials, Phase 1: 3, Phase 2: 1. By status, recruiting: 4, active: 4, completed: 2.
Notable registered trials include:
Peptides referenced: Semaglutide, Retatrutide, Glucagon, GLP-1.
Related reading: MHRA approves orforglipron, Lilly's oral GLP-1 drug, for UK use, AI-designed oral peptides get first commercial test in $100M deal, Meant launches LegitScript-certified GLP-1 telehealth platform, NCI tests neoantigen vaccine in metastatic triple-negative breast cancer.